Cuomo’s ‘COVID Czar’ immediately resigned after losing exemption to ethics laws
Cuomo’s right-hand man for COVID-19 in the state of New York immediately resigned after losing an exemption to ethics laws.
Larry Schwartz stepped down after COVID advisors lost their “volunteer” label, thus making them him subject to ethics laws in the state.
The Post Millennial reported Saturday that COVID-19 advisors had previously not been responsible for disclosing financial information and there were no anti-lobbying provisions in place.
Scwartz has been active in the governor’s response to COVID-19. Cuomo’s secretary Melissa DeRosa tweeted a note of thanks to the now-former COVID “Czar.”
“I can’t think of another public servant who has sacrificed more than Larry Schwartz in their entire career than he has over the last year as a volunteer,” she said.
Read the full story here.
You may like
FDA will work with China to import cancer drugs due to U.S. shortages
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
You may like
Economy5 days ago
New York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
Economy5 days ago
Texas Gov Abbott aims to eliminate property taxes: ‘we must dream big’
Immigration4 days ago
Biden Administration to allow 40,000 asylum-seekers per month into US with mobile app
Featured2 days ago
Las Vegas Backyard UFO Encounter and Its Connection to Historic UFO Incidents